Business Wire

euNetworks Performance Update for Third Quarter 2017


euNetworks is a European facilities based bandwidth infrastructure provider that sells focus products to target customers. Our key drivers of bandwidth growth are data centre and cloud connectivity.

This press release features multimedia. View the full release here:

Brady Rafuse, CEO of euNetworks (Photo: Business Wire)

Brady Rafuse, CEO of euNetworks (Photo: Business Wire)

We delivered a strong performance in the third quarter. Total revenue grew 10% from Q3 2016 reaching €34.9m, with recurring revenue up 9% and recurring revenue from the focus products up 15% from Q3 2016, despite adverse currency impact. Adjusted EBITDA grew 18% from Q3 2016.

Capital investment in Q3 2017 was €17.1m, up 43% from Q3 2016. The majority of capital invested in the quarter was driven by customer projects, as it was in Q2 2017. Some of these metro and long haul developments included:

  • Manchester fibre metro build and roll out of DC Connect in Manchester. We now have 14 operational metro networks, with 7 of these enabled with DC Connect.
  • Scandinavian long haul development, extending from Stockholm on fully diverse paths to Helsinki. The south route is a new system, completely diverse from most existing routes, and due to go live in November. The north route was developed on an existing route into key data centres in Helsinki.
  • Further investment in our German long haul network, delivering highly differentiated, unique and multi-route 100G long haul options for our customers to connect between our metro cities.
  • Lighting our first fibre-based route to Madrid, primarily in support of our financial services customers. This will go live in Q4 2017.
  • Extending our fibre based long haul network reach east, with a diverse fibre ring from Munich via Vienna and Prague to Dresden, going live in Q4 2017.

Sales performance was strong in Q3 2017, delivering 20% growth quarter on quarter and 25% growth from Q3 2016. This followed new network service capabilities going live in 1H 2017 and the benefit from additional sales resource that was added in Q1 2017. euNetworks’ service installations remained high after a good 1H 2017 performance, up 46% from Q3 2016 and in line with Q2 2017. Average churn in the quarter was 0.9%, with disconnections and churn in line with Q3 2016.

Normalised adjusted EBITDA was up 19% from Q3 2016 and up 8% from Q2 2017, reaching €13.1m. Normalised adjusted EBITDA in the quarter was €0.3m higher than adjusted EBITDA due to some professional fee normalisations in the business.

“The performance of the business was solid through Q3 2017, with strong growth in revenue and adjusted EBITDA while we continued to invest capital into the network for our customers,” said Brady Rafuse, Chief Executive Officer of euNetworks. “We had a great sales quarter and service installations remained high. We’ve also maintained our focus on quickly responding to our customers bandwidth needs, with the fibre expansion in Scandinavia, further phases of our German long haul network development, and more projects underway in both existing and new markets going live in Q4 2017 and early in 2018.”

“We remained focused on delivering scalable, fibre based products and solutions to a customer base that is at the centre of the technology transformation,” said Rafuse. “Our ability to operate a growing business while also delivering significant network development projects remains our focus today and in the future.”


Q2 2016

      Q3 2016       Q4 2016       Q1 2017       Q2 2017       Q3 2017               12 mths - 30/9/2016       12 mths - 30/9/2017       %    
Total Revenue 32.2 31.8 32.3 32.6 33.8 34.9 125.2 133.6 6.7
Recurring Revenue 32.2 31.8 32.3 32.6 33.8 34.5 125.2 133.2 6.4
Adjusted EBITDA 10.7 10.8 10.6 10.7 12.5 12.8 41.2 46.6 13.1
Normalised Adjusted EBITDA 11.1 11.0 11.7 11.3 12.1 13.1 41.8 48.2 15.2
LQA Normalised Adjusted EBITDA exit 44.2 44.2 46.7 45.2 48.4 52.5 44.2 52.5 18.8
Capital Expenditure 16.1 11.9 16.5 14.2 16.9 17.1 50.4 64.7 28.5
Proxy Cash flow       (5.6)       (1.1)       (5.9)       (3.5)       (4.4)       (4.3)               (9.2)       (18.1)       n/a

About euNetworks

euNetworks is a bandwidth infrastructure provider, owning and operating 14 fibre based metropolitan networks across Europe connected with a high capacity intercity backbone covering 49 cities in 14 countries. The company leads the market in data centre connectivity, directly connecting over 300 in Europe today. euNetworks is also a leading cloud connectivity provider, directly connecting 13 cloud platforms with access to a further 7. The company offers a portfolio of metropolitan and long haul services including Dark Fibre, Wavelengths, and Ethernet. Wholesale, finance, content, media, data centre and enterprise customers benefit from euNetworks’ unique inventory of fibre and duct based assets that are tailored to fulfil their high bandwidth needs.

euNetworks Group Limited is headquartered in London. For further information please visit

To view the euNetworks map go to

Contact information

Hannah Fox
Senior Director Marketing
hannah_britt skype
+44 20 7952 1338 office
+44 7717 896 446 mobile

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Elliott Welcomes Imminent Bezeq Board Overhaul and New Era for Strong Independent Governance23.3.2018 19:05Tiedote

Elliott Advisors (UK) Limited (“Elliott”), which advises funds which collectively hold a significant economic interest in Bezeq The Israeli Telecommunication Corporation Ltd. (“Bezeq” or the “Company”), welcomes the proposed governance reforms announced by Bezeq last night. In its initial letter to Bezeq Interim Chairman David Granot, dated January 16, 2018, Elliott outlined the urgent need to address the Company’s serious corporate governance issues, and called for changes at the Board level that result in “the right mixture of expertise, independence and integrity for the future.” Elliott stated then, and reiterates now, its belief that “there is significant value to be unlocked if the right steps are taken to improve its corporate governance.” Bezeq has strong business fundamentals, an exemplary workforce, and great potential. Following yesterday’s announcement, Elliott highlights the changes that have occurred since January 16th. Taken together, these amount to a revolution in the

Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 15:52Tiedote

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal

CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 15:50Tiedote

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation

Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 15:46Tiedote

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c

Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 15:00Tiedote

Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at This press release features multimedia. View the full release here: Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on

ViiV Healthcare Gains CHMP Positive Opinion for Juluca (dolutegravir/rilpivirine) in Europe23.3.2018 14:27Tiedote

ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a Positive Opinion recommending marketing authorisation for Juluca (dolutegravir/rilpivirine) for the treatment of HIV infection in adults who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor. The 2-drug regimen comprises dolutegravir 50mg (ViiV Healthcare) and rilpivirine 25mg (Janssen Sciences Ireland UC). Deborah Waterhouse, Chief Executive Officer at ViiV Healthcare commented: “Today is an important milestone for people living with HIV in Europe. It takes us a step closer to offering the first, single-pill, 2-drug regi

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme